MedTrace Logo

NKG2D CAR-NK & Ovarian Cancer

NCT05776355 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-03-28

No results posted yet for this study

Summary

This trial will explore the maximum tolerated dose （MTD）of NKG2D CAR-NK cells in the treatment of platinum-resistant, relapsed epithelial ovarian cancer in a dose-escalation manner, and observe the clinical safety and efficacy.

Conditions

Interventions

BIOLOGICAL

NKG2D CAR-NK

Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion

Sponsors & Collaborators

  • Hangzhou Cheetah Cell Therapeutics Co., Ltd

    lead OTHER

Principal Investigators

  • Zhu JianQing, MD · Zhejiang Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-31
Primary Completion
2024-04-30
Completion
2024-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05776355 on ClinicalTrials.gov